Join the club for FREE to access the whole archive and other member benefits.

MyMD Pharmaceuticals begins phase 2 trial of TNF-inhibitor in January 2022

Potential oral treatment to prevent sarcopenia and frailty, and extend healthy lifespan


Key points from article :

MyMD Pharmaceuticals' lead compound, MYMD-1 to treat autoimmune and age-related diseases, including extending human lifespan.

Starting a Phase 2 human trial in January 2022, targeting sarcopenia as its primary endpoint.

“We have 14 patents issued for MyMD-1,” - Adam Kaplin, CSO at MyMD.

Focus on “markers like muscle loss, weakness, frailty, and increased predisposition for age-related pathology.”

It reduces chronic inflammation through inhibition of several cytokines, including TNF alpha.

“It’s the first proinflammatory cytokine to go up when you get an infection/inflammatory illness, and it turns on IL-6 and IL-1.”

It is also selective and able to cross the blood brain barrier.

“ shut down the inflammation and measure sarcopenia over time in at-risk population,” - Kaplin.

Followed by a 6-month trial in people with increased signs of inflammation.

Efficacy data is expected by the end of the first quarter of 2022.

Mentioned in this article:

Click on resource name for more details.

Adam Kaplin

Chief Scientific Officer of MyMD Pharmaceuticals

MyMD Pharmaceuticals

Pharmaceutical company developing novel immunotherapies to extend human lifespan

Topics mentioned on this page:
Sarcopenia, Inflammaging